CNS PHARMACEUTICALS, INC.

(CNSP)
  Rapport
Vertraagde tijd Nasdaq  -  22:00 01-07-2022
0.2650 USD   -5.36%
23/06CNS Pharmaceuticals krijgt FDA-goedkeuring voor uitbreiding van het aantal patiënten dat in aanmerking komt voor een proef met hersenkankerbehandeling; aandelen stijgen
MT
23/06CNS Pharmaceuticals Inc. Krijgt goedkeuring van U.S. FDA voor wijziging van protocol in lopende potentieel cruciale wereldwijde studie ter evaluatie van berubicine voor de behandeling van GBM
CI
08/06CNS Pharmaceuticals, Inc. Kondigt de presentatie aan van het lopende potentieel beslissende ontwerp van de klinische studie met berubicine op de jaarlijkse bijeenkomst van de American Society of Clinical Oncology (ASCO) in 2022
CI
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproducten 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiŽle publicatiesSectornieuws
Nieuws in andere talen op CNS PHARMACEUTICALS, INC.
23/06CNS Pharmaceuticals Gets FDA Approval to Expand Patient Eligibility in Trial of Brain C..
23/06CNS Pharmaceuticals Receives Approval from U.S. FDA for Protocol Amendment to Ongoing P..
23/06CNS Pharmaceuticals Inc. Receives Approval from U.S. FDA for Protocol Amendment to Ongo..
08/06CNS Pharmaceuticals, Inc. Announces Presentation of Ongoing Potentially Pivotal Berubic..
24/05CNS Pharmaceuticals Announces Presentation at the H.C. Wainwright Global Investment Con..
16/05CNS Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate..
13/05CNS PHARMACEUTICALS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION ..
13/05CNS Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31..
28/04CNS Pharmaceuticals Receives Approval from Ethics Committee and Competent Authority in ..
28/04CNS Pharmaceuticals Receives Approval for Pivotal Study of Berubicin for Treatment of G..
12/04CNS Pharmaceuticals to Participate in the Virtual Investor Glioblastoma Multiforme (GBM..
06/04CNS Pharmaceuticals Gets French Approval for Brain Cancer Treatment Study
06/04CNS Pharmaceuticals Receives Approval from France Ethics Committee and Competent Author..
05/04SECTOR UPDATE : Health Care Stocks Resist Late Tuesday Selloff
05/04SECTOR UPDATE : Health Care
05/04CNS Pharmaceuticals Gets Swiss Approval for Brain Cancer Treatment Study; Shares Jump
05/04CNS Pharmaceuticals Gets Swiss Approval for Brain Cancer Treatment Study
05/04CNS Pharmaceuticals Receives Approval from Competent Authority of Switzerland for Poten..
05/04CNS Pharmaceuticals, Inc. Receives Approval from Competent Authority of Switzerland for..
23/03CNS Pharmaceuticals to Participate in the 2022 Virtual Growth Conference Presented by M..
09/03CNS Pharmaceuticals Reiterates Operational Progress and Addresses Recent Share Price Ac..
03/03CNS PHARMACEUTICALS : Reports Full Year 2021 Financial Results and Provides Corporate Upda..
03/03CNS PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition ..
03/03CNS Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Corporate Upd..
03/03CNS Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31,..
03/03CNS Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt
18/02CNS PHARMACEUTICALS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing ..
01/02WPD Pharmaceuticals Secures Berubicin Sub-License Rights in Perpetuity
20/01CNS Pharmaceuticals to Present at the Virtual Investor 2022 Top Picks Conference
10/01CNS Pharmaceuticals Announces Closing of $11.5 Million Private Placement Priced At-the-..
10/01CNS PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (f..
07/01CNS Pharmaceuticals to Present at the H.C. Wainwright BioConnect Conference
06/01Health Care Stocks Ending Near Intra-Day Lows
06/01SECTOR UPDATE : Health Care
06/01CNS Pharmaceuticals to Raise $11.5 Million in Private Placement
06/01Wall Street Set for Mixed Open After Fed-Induced Retreat
06/01CNS PHARMACEUTICALS : Announces $11.5 Million Private Placement Priced At-the-Market Under..
06/01CNS PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Unregistered Sale ..
06/01Top Premarket Decliners
06/01CNS Pharmaceuticals Announces $11.5 Million Private Placement Priced At-the-Market Unde..
05/01CNS Pharmaceuticals, Inc. announced that it expects to receive $11.500001 million in fu..
2021CNS PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (f..
2021CNS Pharma Secures Switzerland Ethics Committee Nod For Trial of Brain Cancer Drug Cand..
2021CNS Pharmaceuticals Receives Approval from Switzerland Ethics Committee for its Potenti..
2021CNS Pharmaceuticals, Inc. Receives Approval from Switzerland Ethics Committee for its P..
2021TRANSCRIPT : CNS Pharmaceuticals, Inc. Presents at Virtual Investor Roundtable Event, Nov-..
2021CNS Pharmaceuticals to Present at the Virtual Investor Roundtable Event
2021CNS PHARMACEUTICALS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION ..
2021CNS Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Month..
2021CNS PHARMACEUTICALS : Featured in Syndicated Broadcast Covering Dosing of First Patients i..
2021CNS PHARMACEUTICALS : Starts Dosing in Trial of Berubicin Chemotherapy for Brain Cancer
2021CNS PHARMACEUTICALS : Doses First Group of Patients with Berubicin, an FDA-Designated Fast..
2021CNS Pharmaceuticals Doses First Group of Patients with Berubicin, an FDA-Designated Fas..
2021CNS PHARMACEUTICALS : Reports Second Quarter 2021 Financial Results and Provides Business ..
2021CNS Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter Ended June 3..
2021CNS PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESU..
2021CNS PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (f..
2021WESTCOT VENTURES : WPD Pharmaceuticals' Licensor Receives FDA Fast Track Designation For B..
2021CNS PHARMACEUTICALS' : Berubicin Receives FDA Fast-Track Designation; Shares Climb
2021CNS PHARMACEUTICALS : Continues to Execute on Corporate, Clinical and Regulatory Strategie..
2021CNS PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders, Other Eve..
2021CNS PHARMACEUTICALS' : Berubicin Receives Fast-Track FDA Status; Shares Climb
2021CNS PHARMACEUTICALS : FDA Grants Fast Track Designation to CNS Pharmaceuticals for Berubic..
2021FDA Grants Fast Track Designation to CNS Pharmaceuticals, Inc. for Berubicin for the Tr..
2021CNS PHARMACEUTICALS : Announces Inclusion in the Russell 2000ģ Index
2021CNS PHARMACEUTICALS : Starts Enrollment in Study of Berubicin for Progressive Type of Brai..
2021CNS PHARMACEUTICALS : Commences Patient Enrollment in Potentially Pivotal Study of Berubic..
2021CNS Pharmaceuticals Commences Patient Enrollment in Potentially Pivotal Study of Berubi..
2021CNS PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (f..
2021CNS PHARMACEUTICALS : Reports First Quarter 2021 Financial Results and Provides Business O..
2021CNS Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31..
2021CNS PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESU..
2021CNS PHARMACEUTICALS : to Present at the Q2 Virtual Investor Summit
2021Certain Common Stock of CNS Pharmaceuticals, Inc. are subject to a Lock-Up Agreement En..
2021Certain Warrants of CNS Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Endin..
1  2  3  4Volgende
Volgende evenement op CNS PHARMACEUTICALS, INC.